Top ▲

SLC47 family of multidrug and toxin extrusion transporters C

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).

Overview

Click here for help

« Hide

Human multidrug and toxin extrusion MATE1 and MATE2-K are H+/organic cation antiporters [1]. They are predominantly expressed in the kidney and play a role in renal tubular secretion of cationic drugs.

Transporters

1216
Click here for help

Targets of relevance to immunopharmacology are highlighted in blue

MATE1 (Multidrug and toxin extrusion / SLC47A1) C Show summary »


Target Id 1216
Nomenclature Multidrug and toxin extrusion
Systematic nomenclature SLC47A1
Common abbreviation MATE1
Previous and unofficial names H+/organic cation antiporter variant 1 | H+/organic cation antiporter variant 2 | solute carrier family 47, member 1 | solute carrier family 47 (multidrug and toxin extrusion), member 1 | solute carrier family 47
Genes SLC47A1 (Hs), Slc47a1 (Mm), Slc47a1 (Rn)
Ensembl ID ENSG00000142494 (Hs), ENSMUSG00000010122 (Mm), ENSRNOG00000057404 (Rn)
UniProtKB AC Q96FL8 (Hs), Q8K0H1 (Mm), Q5I0E9 (Rn)
Bioparadigms SLC Tables SLC47A1 (Hs)
RESOLUTE SLC47A1 (Hs)
Endogenous substrates
creatine [7]
thiamine [7]
Substrates
quinidine [7]
paraquat [2]
cephradine [7]
cephalexin [7]
cimetidine pKm 3.8 [5,7]
metformin pKm 3.1 [7]
Sub/family-selective inhibitors
pyrimethamine pKi 7.1 [3]
cimetidine pKi 6.0 [9]
Labelled ligands
[14C]metformin [7-8]
[14C]TEA [6,8]

MATE2-K (MATE2 / SLC47A2) C Show summary »

Comments

Click here for help

Show »

Further reading

Click here for help

Show »

References

Click here for help

Show »

NC-IUPHAR subcommittee and family contributors

Show »

How to cite this family page

Database page citation (select format):

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA et al. (2023) The Concise Guide to PHARMACOLOGY 2023/24: Transporters. Br J Pharmacol. 180 Suppl 2:S374-469.